Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 4/2014

01-08-2014 | Original Article

Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes

Authors: Cinzia Ciccacci, Roberto Morganti, Davide Di Fusco, Cinzia D’Amato, Laura Cacciotti, Carla Greco, Sara Rufini, Giuseppe Novelli, Federica Sangiuolo, Girolama A. Marfia, Paola Borgiani, Vincenza Spallone

Published in: Acta Diabetologica | Issue 4/2014

Login to get access

Abstract

Diabetic polyneuropathy (DPN) and cardiovascular autonomic neuropathy (CAN) are common type 2 diabetes complications with a large inter-individual variability in terms of clinical manifestations and severity. Our aim was to evaluate a possible involvement of genetic polymorphisms in miRNA regions in the susceptibility to DPN and CAN. Nine polymorphisms in miRNA genes were studied in a sample of 132 type 2 diabetes patients (T2D) analysed for DPN and 128 T2D patients analysed for CAN. A genotype–phenotype correlation analysis was performed. The T allele of rs11888095 single nucleotide polymorphism (SNP) in MIR128a was significantly associated with a higher risk (ORadj = 4.89, P adj = 0.02), whereas the C allele of rs2910164 SNP in MIR146a was associated with a lower risk to develop DPN (ORadj = 0.49, P adj = 0.09), respectively. A multivariate logistic regression analysis confirmed that both SNPs contribute to DPN (p < 0.001 and p = 0.01 for MIR128a and MIR146a, respectively). MIR128a SNP significantly contributed also to DPN score (p = 0.026). Rs895819 SNP in MIR27a was significantly associated with a higher risk to develop early CAN (P adj = 0.023 and ORadj = 3.43). The rs2910164 SNP in MIR146a showed a protective effect respect to early CAN (P adj = 0.052, ORadj = 0.32) and to confirmed CAN (P adj = 0.041, ORadj = 0.13). The same SNP resulted significantly associated with a lower CAN score and a higher E/I (p = 0.002 and p = 0.003, respectively). In conclusion, we described associations of MIR128a and MIR146a SNPs with DPN susceptibility and of MIR146a and MIR27a SNPs with CAN susceptibility. This is the first study showing that genetic variability in miRNA genes could be involved in diabetic neuropathies susceptibility.
Appendix
Available only for authorised users
Literature
1.
Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O’Brien PC, Russell JW; on behalf of the Toronto Expert Panel on Diabetic Neuropathy* (2011) Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev doi: 10.​1002/​dmrr.​1226
2.
Yagihashi S, Mizukami H, Sugimoto K (2011) Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Invest 2(1):18–32CrossRef
3.
Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusanio F (1997) A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian diabetic neuropathy committee. Diabetes Care 20(5):836–843PubMedCrossRef
4.
Várkonyi T, Kempler P (2008) Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 10:99–108PubMed
5.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10):2285–2293CrossRef
6.
Gries FA, Cameron NE, Low PA, Ziegler D (2003) Textbook of diabetic neuropathy. Thieme, Stuttgard, pp 64–82
7.
Papanas N, Vinik AI, Ziegler D (2011) Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 7:682–690PubMed
8.
Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, Melga P, Viviani GL, Esposito K, Morganti R, Cortelli P; Diabetic Neuropathy Study Group of the Italian Society of Diabetology (2011) Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 21(1):69–78CrossRef
9.
Töyry JP, Partanen JV, Niskanen LK, Länsimies EA, Uusitupa MI (1997) Divergent development of autonomic and peripheral somatic neuropathies in NIDDM. Diabetologia 40(8):953–958PubMedCrossRef
10.
Gaede P, Pedersen O (2004) Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 53(Suppl 3):S39–S47PubMedCrossRef
11.
Jurado J, Ybarra J, Romeo JH, Garcia M, Zabaleta-Del-Olmo E (2012) Angiotensin-converting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study. J Diabetes Complicat 26(2):77–82PubMedCrossRef
12.
Mansoor Q, Javaid A, Bilal N, Ismail M (2012) Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus. J Diabetes 4(3):257–261PubMedCrossRef
13.
Yigit S, Karakus N, Inanir A (2013) Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy. Mol Vis 19:1626–1630PubMedCentralPubMed
14.
Vojtková J, Ďurdík P, Čiljaková M, Michnová Z, Turčan T, Babušíková E (2013) The association between glutathione S-transferase T1 and M1 gene polymorphisms and cardiovascular autonomic neuropathy in Slovak adolescents with type 1 diabetes mellitus. J Diabetes Complicat 27(1):44–48PubMedCrossRef
15.
Karolina DS, Armugam A, Sepramaniam S (2012) MiRNAs and diabetes mellitus. Expert Rev Endocrinol Metab 7(3):281–300CrossRef
16.
17.
Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, Sommer SS, Rossi JJ (2009) SNPs in human miRNA genes affect biogenesis and function. RNA 15(9):1640–1651PubMedCentralPubMedCrossRef
18.
Ciccacci C, Di Fusco D, Cacciotti L, Morganti R, D’Amato C, Greco C, Rufini S, Novelli G, Sangiuolo F, Spallone V, Borgiani P (2013) MicroRNA genetic variations: association with type 2 diabetes. Acta Diabetol 50(6):867–872PubMedCrossRef
19.
Bril V, Perkins BA (2002) Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care 25(11):2048–2052PubMedCrossRef
20.
Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D (1996) Reproducibility of Michigan neuropathy screening instrument (MNSI): a comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care 19(8):904–905PubMed
21.
Zinman LH, Bril V, Perkins BA (2004) Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments. Diabetes Care 27(7):1674–1679PubMedCrossRef
22.
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36PubMedCrossRef
23.
Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA (2012) Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med 29:578–585PubMedCrossRef
24.
Stålberg E, Falck B, Gilai A, Jabre J, Sonoo M, Todnem K (1999) Standards for quantification of EMG and neurography. The international federation of clinical neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 52:213–220PubMed
25.
Dunnigan SK, Ebadi H, Breiner A, Katzberg HD, Lovblom LE, Perkins BA, Bril V (2013) Conduction slowing in diabetic sensorimotor polyneuropathy. Diabetes Care 36:3684–3690PubMedCrossRef
26.
27.
Lorenzen J, Kumarswamy R, Dangwal S, Thum T (2012) MicroRNAs in diabetes and diabetes-associated complications. RNA Biol 9(6):820–827PubMedCrossRef
28.
Kovacs B, Lumayag S, Cowan C, Xu S (2011) MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 52(7):4402–4409PubMedCrossRef
29.
Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, Feldman RD, Chakrabarti S (2011) miR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60(11):2975–2984PubMedCentralPubMedCrossRef
30.
McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S (2011) MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 60(4):1314–1323PubMedCentralPubMedCrossRef
31.
Silva VA, Polesskaya A, Sousa TA, Corrêa VM, André ND, Reis RI, Kettelhut IC, Harel-Bellan A, De Lucca FL (2011) Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol Vis 17:2228–2240PubMedCentralPubMed
32.
Du B, Ma LM, Huang MB, Zhou H, Huang HL, Shao P, Chen YQ, Qu LH (2010) High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 584(4):811–816PubMedCrossRef
33.
Srivastava K, Srivastava A (2012) Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One 7(11):e50966PubMedCentralPubMedCrossRef
34.
Wang PY, Gao ZH, Jiang ZH, Li XX, Jiang BF, Xie SY (2013) The associations of single nucleotide polymorphisms in miR-146a, miR-196a and miR-499 with breast cancer susceptibility. PLoS One 8(9):e70656PubMedCentralPubMedCrossRef
35.
Chen HF, Hu TT, Zheng XY, Li MQ, Luo MH, Yao YX, Chen Q, Yu SY (2013) Association between miR-146a rs2910164 polymorphism and autoimmune diseases susceptibility: a meta-analysis. Gene 521(2):259–264PubMedCrossRef
36.
Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, Qian X, Tang Y, Lau YL, de Vries N, Tak PP, Tsao BP, Shen N (2011) A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7(6):e1002128PubMedCentralPubMedCrossRef
37.
Yang B, Zhang JL, Shi YY, Li DD, Chen J, Huang ZC, Cai B, Song XB, Li LX, Ying BW, Wang LL (2011) Association study of single nucleotide polymorphisms in pre-miRNA and rheumatoid arthritis in a Han Chinese population. Mol Biol Rep 38(8):4913–4919PubMedCrossRef
38.
Green MJ, Cairns MJ, Wu J, Dragovic M, Jablensky A, Tooney PA, Scott RJ, Carr VJ, Australian Schizophrenia Research Bank (2013) Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol Psychiatry 18(7):774–780PubMedCrossRef
39.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthr Rheum 60:1065–1075CrossRef
40.
Li D, Wang T, Song X, Qucuo M, Yang B, Zhang J, Wang J, Ying B, Tao C, Wang L (2011) Genetic study of two single nucleotide polymorphisms within corresponding microRNAs and susceptibility to tuberculosis in a Chinese Tibetan and Han population. Hum Immunol 72(7):598–602PubMedCrossRef
41.
Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, de la Chapelle A (2009) Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA 106(5):1502–1505PubMedCentralPubMedCrossRef
42.
Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, Mohan V (2011) Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 351(1–2):197–205PubMedCrossRef
43.
Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X (2009) MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183:2150–2158PubMedCrossRef
44.
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC (2008) Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27(42):5643–5647PubMedCentralPubMedCrossRef
45.
Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthr Res Ther 10:R101CrossRef
46.
Ramkaran P, Khan S, Phulukdaree A, Moodley D, Chuturgoon AA (2013) miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease. Cell Biochem Biophys. doi:10.​1007/​s12013-013-9704-7
47.
Cameron NE, Cotter MA (2008) Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Target 9(1):60–67CrossRef
48.
Obrosova IG (2009) Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6(4):638–647PubMedCrossRef
49.
Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T, Döring A, Thorand B, Holle R, Giani G, Martin S, Meisinger C (2009) Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA survey F3 (Augsburg, Germany). Diabetes Care 32(4):680–682PubMedCentralPubMedCrossRef
50.
Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A (2009) Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 94(6):2157–2163PubMedCentralPubMedCrossRef
51.
Spallone V, Greco C (2013) Painful and painless diabetic neuropathy: one disease or two? Curr Diabetes Rep 13(4):533–549CrossRef
52.
Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF (2004) Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 25(5):363–370PubMedCrossRef
53.
Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T (2007) RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 13(3–4):178–184PubMedCentralPubMed
54.
Lanza GA, Pitocco D, Navarese EP, Sestito A, Sgueglia GA, Manto A, Infusino F, Musella T, Ghirlanda G, Crea F (2007) Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. Eur Heart J 28(7):814–820PubMedCrossRef
55.
Lieb DC, Parson HK, Mamikunian G, Vinik AI (2012) Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res 2012:878760PubMedCentralPubMedCrossRef
56.
Grant RW, Moore AF, Florez JC (2009) Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care 32(6):1107–1114PubMedCentralPubMedCrossRef
57.
Motohashi N, Alexander MS, Shimizu-Motohashi Y, Myers JA, Kawahara G, Kunkel LM (2013) Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis. J Cell Sci 126(Pt 12):2678–2691PubMedCentralPubMedCrossRef
58.
Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE (2011) Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 134(Pt 12):3578–3589PubMedCrossRef
59.
Narasimhan M, Patel D, Vedpathak D, Rathinam M, Henderson G, Mahimainathan L (2012) Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells. PLoS One 7(12):e51111PubMedCentralPubMedCrossRef
Metadata
Title
Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes
Authors
Cinzia Ciccacci
Roberto Morganti
Davide Di Fusco
Cinzia D’Amato
Laura Cacciotti
Carla Greco
Sara Rufini
Giuseppe Novelli
Federica Sangiuolo
Girolama A. Marfia
Paola Borgiani
Vincenza Spallone
Publication date
01-08-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0582-2

Other articles of this Issue 4/2014

Acta Diabetologica 4/2014 Go to the issue

Original Article

Non-dipping and arterial hypertension depend on clinical factors rather than on genetic variability of ACE and RGS2 genes in patients with type 1 diabetes

Original Article

Glycogen storage in the human retinal pigment epithelium: a comparative study of diabetic and non-diabetic donors

Original Article

Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of aldosterone synthase

Original Article

Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes

Original Article

Lower vitamin D levels at first trimester are associated with higher risk of developing gestational diabetes mellitus

Short Communication

Evidence for altered transport of insulin across the blood–brain barrier in insulin-resistant humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits